VLM + VIT + CIR

**VLM + VIT + CIR** is a preclinical multi-component **DNA or RNA-based gene therapy** being developed by **Virothera** for **CCR5-positive and chemokine receptor-driven breast cancer**. The program combines **VLM** as a virus-like membrane antigen-delivery platform, **VIT** as an immunostimulatory chemokine-receptor-binding component that is described as binding without signaling to inhibit T regulatory cell activity, and **CIR** as a cytokine immune regulator that binds and signals regulatory chemokine receptors. Together, these components are intended to modulate **T regulatory cells** and enhance anti-tumor immunity in cancers driven by **CCR5 and related chemokine receptors**. The program appears to remain at the **preclinical discovery or early-stage** level, with no clinical-stage development identified.

Other names

VLM/VIT/CIR breast cancer program